Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1CNS 1

Conditions

Melanoma 8Multiple Myeloma 4Glioma 4Thyroid Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lymphoma 2Lung Neoplasms 2Hematologic Neoplasms 2Glioblastoma 2Colorectal Neoplasms 2Astrocytoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Sarcoma 1Refractory Differentiated Thyroid Gland Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation 1

Interventions

trametinib 1gallium Ga 68 dotatate 1dabrafenib 1Magnetic Resonance Spectroscopy 1Ga(III)-DOTATOC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ganglioneuroma × dabrafenib × 90 days × Clear all
NCT03975829 2026-06-02

Pediatric Long-Term Follow-up and Rollover Study

Novartis

Phase 4 Recruiting
165 enrolled
CNSMyeloid

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡